Novel type 1 photosensitizers: viability of leukemia cells exposed to reactive intermediates generated in situ by in vitro photofragmentation

Photodynamic therapy of tumors involving Type 2 photosenstizers has been conspicuously successful, but the Type 1 process, in contrast, has not received much attention despite its considerable potential. Accordingly, several classes of molecules containing fragile bonds such as azido (-N=N=N), azo (-N=N-), sulfenato (-S-O-) and oxaza (-N-O-) functional groups that produce reactive intermediates such as radicals and nitrenes upon photoexcitation were prepared and tested for cell viability using U397 leukemia cell line. The azido photosensitizer was conjugated to leukemia cell binding peptide, SFFWRLS, for targeted cell viability study. The cells were incubated with the photosensitizer at various concentrations, and were illuminated for 5, 10, and 20 minutes. The results show that all the photosensitizers caused cell death compared to the controls when exposed to both the photosensitizers and light. Most importantly, selective cell death was observed with the azido peptide conjugate 6, which clearly demonstrates that these Type 1 sensitizers are useful for phototherapeutic applications.

[1]  R. Boyle,et al.  Structure and Biodistribution Relationships of Photodynamic Sensitizers * , 1996, Photochemistry and photobiology.

[2]  Raghavan Rajagopalan,et al.  Targeted Type 1 phototherapeutic agents using azido-peptide bioconjugates , 2001, SPIE BiOS.

[3]  R. Rajagopalan,et al.  Chemistry of bifunctional photoprobes. 6. Synthesis and characterization of high specific activity metalated photochemical probes: development of novel rhenium photoconjugates of human serum albumin and fab fragments. , 2002, The Journal of organic chemistry.

[4]  Tayyaba Hasan,et al.  Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.

[5]  J. Sessler,et al.  Texaphyrins: a new approach to drug development , 2001 .

[6]  H. Saiki,et al.  Photochemical behaviour of cyclic imino ethers: The NO bond fission, syn—anti isomerization and cycloaddition reactions in the CNO chromophore☆ , 1981 .

[7]  D. Kessel,et al.  Rapid Initiation of Apoptosis by Photodynamic Therapy , 1996, Photochemistry and photobiology.

[8]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[9]  U. Schmidt-Erfurth,et al.  Photodynamic therapy in ocular vascular disease , 1996 .

[10]  Li-bo Li,et al.  Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma. , 2006, Photodiagnosis and photodynamic therapy.

[11]  Daniel B. Shin,et al.  Photofrin Uptake in the Tumor and Normal Tissues of Patients Receiving Intraperitoneal Photodynamic Therapy , 2006, Clinical Cancer Research.

[12]  M Pauer,et al.  Photodynamic therapy for gastrointestinal tumors using three photosensitizers--ALA induced PPIX, Photofrin and MTHPC. A pilot study. , 1998, Neoplasma.

[13]  O. Chapman,et al.  Photolysis of dihydro-1,2-oxazines , 1969 .

[14]  M. Cooney,et al.  History of photodynamic therapy. , 1999, International ophthalmology clinics.

[15]  D. Pasto,et al.  Demonstration of the synthetic utility of the generation of alkoxy radicals by the photo-induced homolytic dissociation of alkyl 4-nitrobenzenesulfenates , 1994 .

[16]  G. Krueger Current concepts and review of alefacept in the treatment of psoriasis. , 2004, Dermatologic clinics.

[17]  T. Dougherty,et al.  Studies on the mechanism of tumor destruction by photoradiation therapy. , 1984, Progress in clinical and biological research.

[18]  R. Saxton,et al.  Evaluation of four new carbocyanine dyes for photodynamic therapy with lasers , 1994, The Laryngoscope.

[19]  D. Mitton,et al.  Photodynamic therapy for Barrett's oesophagus and oesophageal carcinoma-How I do it. , 2006, Photodiagnosis and photodynamic therapy.

[20]  J. Sessler,et al.  Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. , 2000, Biochemical pharmacology.

[21]  A. Reiser,et al.  Photolysis of aromatic azides. Part 3.—Quantum yield and mechanism , 1968 .

[22]  W. Cheong,et al.  Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy. , 2000, Circulation.

[23]  S. Springs,et al.  Biomedical applications of lanthanide (III) texaphyrins Lutetium(III) texaphyrins as potential photodynamic therapy photosensitizers , 1997 .

[24]  K. Koehler,et al.  New synthesis of .beta.-lactams based on nitrone cycloaddition to nitroalkenes , 1984 .

[25]  T. Dougherty Photochemistry in the treatment of cancer , 1993 .

[26]  C. Hendrich,et al.  Photodynamic therapy for rheumatoid arthritis? , 1997, Lasers in surgery and medicine.

[27]  H. Bergh,et al.  Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II. , 1998, British Journal of Cancer.